SALT LAKE CITY, Feb. 22, 2022 /PRNewswire/ PolarityTE, Inc. (Nasdaq: PTE) today announced results from a multi-center randomized controlled tri.
PolarityTE: SkinTE Meets Primary Endpoints In Final Analysis From Diabetic Foot Ulcer Trial
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
(PTE) - PolarityTE Stock Jumps As SkinTE Aces Diabetic Foot Ulcer Trial
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
PolarityTE: Diabetic Foot Ulcer Trial Meets Primary And Secondary Endpoint
WASHINGTON (dpa-AFX) - PolarityTE Inc. (PTE) said that a multi-center randomized controlled trial evaluating treatment of Diabetic Foot Ulcers with SkinTE plus standard of care compared to standard of care alone met the primary endpoint of wound closure at 12 weeks and secondary endpoint of Percent Area Reduction or PAR at 12 weeks.
The company said 100 patients were evaluated across 13 sites with 50 patients receiving SkinTE plus standard of care and 50 patients receiving standard of care alone.
The company noted that 70% of patients receiving SkinTE plus standard of care had wound closure at 12 weeks versus 34% of patients receiving standard of care alone.